Effect of oral administration of pimobendan in cats with heart failure

Sonya G. Gordon, Ashley B. Saunders, Risa M. Roland, Randolph L. Winter, Lori Drourr, Sarah E. Achen, Crystal D. Hariu, Ryan C. Fries, May M. Boggess, Matthew W. Miller

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective-To determine the effect of PO administration of pimobendan on clinical and echocardiographic variables and survival time in cats with heart failure characterized by ventricular systolic dysfunction. Design-Retrospective cohort study. Animals-27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0.26 ± 0.08 mg/kg [0.118 ± 0.036 mg/lb], PO, q 12 h).Procedures-Information on medical history, laboratory results, diagnostic imaging findings, treatments received, and survival time were obtained from medical records of cats that received pimobendan because of cardiac disease. When possible, additional follow-up information was obtained through telephone interviews with referring veterinarians and owners. Results-The mean ± SD age of all 27 cats was 8.9 ± 5.2 years. All cats had received several cardiac medications. Types of heart disease represented included unclassified cardio-myopathy (CM; n = 11 [41%]), dilated CM (8 [30%]), arrhythmogenic right ventricular CM (4 [15%]), congenital heart disease (3 [11%]), and hypertrophic CM with regional hypokinesis (1 [4%]). All cats had ventricular systolic dysfunction. One cat with systolic anterior motion of the mitral valve became severely hypotensive after initial administration of pimobendan and was excluded from the survival analysis. Median survival time was 167 days (95% confidence interval, 32 to 339 days).Conclusions and Clinical Relevance-Pimobendan appeared to be well tolerated in cats with heart failure characterized by ventricular systolic dysfunction of various etiologies. Cats with systolic anterior motion of the mitral valve may develop systemic hypotension when treated with pimobendan. Additional studies are needed to establish dosages for pimobendan and its effects before it can be recommended for treatment of cats with CHF.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalJournal of the American Veterinary Medical Association
Volume241
Issue number1
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

heart failure
oral administration
Oral Administration
Cats
Heart Failure
cats
Ventricular Dysfunction
heart diseases
Heart Diseases
Mitral Valve
pimobendan
medical history
Veterinarians
hypotension
cardiomyopathy
Muscular Diseases
Diagnostic Imaging
Survival Analysis
dosage
cohort studies

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Gordon, S. G., Saunders, A. B., Roland, R. M., Winter, R. L., Drourr, L., Achen, S. E., ... Miller, M. W. (2012). Effect of oral administration of pimobendan in cats with heart failure. Journal of the American Veterinary Medical Association, 241(1), 89-94. https://doi.org/10.2460/javma.241.1.89

Effect of oral administration of pimobendan in cats with heart failure. / Gordon, Sonya G.; Saunders, Ashley B.; Roland, Risa M.; Winter, Randolph L.; Drourr, Lori; Achen, Sarah E.; Hariu, Crystal D.; Fries, Ryan C.; Boggess, May M.; Miller, Matthew W.

In: Journal of the American Veterinary Medical Association, Vol. 241, No. 1, 07.2012, p. 89-94.

Research output: Contribution to journalArticle

Gordon, SG, Saunders, AB, Roland, RM, Winter, RL, Drourr, L, Achen, SE, Hariu, CD, Fries, RC, Boggess, MM & Miller, MW 2012, 'Effect of oral administration of pimobendan in cats with heart failure', Journal of the American Veterinary Medical Association, vol. 241, no. 1, pp. 89-94. https://doi.org/10.2460/javma.241.1.89
Gordon, Sonya G. ; Saunders, Ashley B. ; Roland, Risa M. ; Winter, Randolph L. ; Drourr, Lori ; Achen, Sarah E. ; Hariu, Crystal D. ; Fries, Ryan C. ; Boggess, May M. ; Miller, Matthew W. / Effect of oral administration of pimobendan in cats with heart failure. In: Journal of the American Veterinary Medical Association. 2012 ; Vol. 241, No. 1. pp. 89-94.
@article{d44f11d0787b434aaa3093bfbdfe6721,
title = "Effect of oral administration of pimobendan in cats with heart failure",
abstract = "Objective-To determine the effect of PO administration of pimobendan on clinical and echocardiographic variables and survival time in cats with heart failure characterized by ventricular systolic dysfunction. Design-Retrospective cohort study. Animals-27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0.26 ± 0.08 mg/kg [0.118 ± 0.036 mg/lb], PO, q 12 h).Procedures-Information on medical history, laboratory results, diagnostic imaging findings, treatments received, and survival time were obtained from medical records of cats that received pimobendan because of cardiac disease. When possible, additional follow-up information was obtained through telephone interviews with referring veterinarians and owners. Results-The mean ± SD age of all 27 cats was 8.9 ± 5.2 years. All cats had received several cardiac medications. Types of heart disease represented included unclassified cardio-myopathy (CM; n = 11 [41{\%}]), dilated CM (8 [30{\%}]), arrhythmogenic right ventricular CM (4 [15{\%}]), congenital heart disease (3 [11{\%}]), and hypertrophic CM with regional hypokinesis (1 [4{\%}]). All cats had ventricular systolic dysfunction. One cat with systolic anterior motion of the mitral valve became severely hypotensive after initial administration of pimobendan and was excluded from the survival analysis. Median survival time was 167 days (95{\%} confidence interval, 32 to 339 days).Conclusions and Clinical Relevance-Pimobendan appeared to be well tolerated in cats with heart failure characterized by ventricular systolic dysfunction of various etiologies. Cats with systolic anterior motion of the mitral valve may develop systemic hypotension when treated with pimobendan. Additional studies are needed to establish dosages for pimobendan and its effects before it can be recommended for treatment of cats with CHF.",
author = "Gordon, {Sonya G.} and Saunders, {Ashley B.} and Roland, {Risa M.} and Winter, {Randolph L.} and Lori Drourr and Achen, {Sarah E.} and Hariu, {Crystal D.} and Fries, {Ryan C.} and Boggess, {May M.} and Miller, {Matthew W.}",
year = "2012",
month = "7",
doi = "10.2460/javma.241.1.89",
language = "English (US)",
volume = "241",
pages = "89--94",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "1",

}

TY - JOUR

T1 - Effect of oral administration of pimobendan in cats with heart failure

AU - Gordon, Sonya G.

AU - Saunders, Ashley B.

AU - Roland, Risa M.

AU - Winter, Randolph L.

AU - Drourr, Lori

AU - Achen, Sarah E.

AU - Hariu, Crystal D.

AU - Fries, Ryan C.

AU - Boggess, May M.

AU - Miller, Matthew W.

PY - 2012/7

Y1 - 2012/7

N2 - Objective-To determine the effect of PO administration of pimobendan on clinical and echocardiographic variables and survival time in cats with heart failure characterized by ventricular systolic dysfunction. Design-Retrospective cohort study. Animals-27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0.26 ± 0.08 mg/kg [0.118 ± 0.036 mg/lb], PO, q 12 h).Procedures-Information on medical history, laboratory results, diagnostic imaging findings, treatments received, and survival time were obtained from medical records of cats that received pimobendan because of cardiac disease. When possible, additional follow-up information was obtained through telephone interviews with referring veterinarians and owners. Results-The mean ± SD age of all 27 cats was 8.9 ± 5.2 years. All cats had received several cardiac medications. Types of heart disease represented included unclassified cardio-myopathy (CM; n = 11 [41%]), dilated CM (8 [30%]), arrhythmogenic right ventricular CM (4 [15%]), congenital heart disease (3 [11%]), and hypertrophic CM with regional hypokinesis (1 [4%]). All cats had ventricular systolic dysfunction. One cat with systolic anterior motion of the mitral valve became severely hypotensive after initial administration of pimobendan and was excluded from the survival analysis. Median survival time was 167 days (95% confidence interval, 32 to 339 days).Conclusions and Clinical Relevance-Pimobendan appeared to be well tolerated in cats with heart failure characterized by ventricular systolic dysfunction of various etiologies. Cats with systolic anterior motion of the mitral valve may develop systemic hypotension when treated with pimobendan. Additional studies are needed to establish dosages for pimobendan and its effects before it can be recommended for treatment of cats with CHF.

AB - Objective-To determine the effect of PO administration of pimobendan on clinical and echocardiographic variables and survival time in cats with heart failure characterized by ventricular systolic dysfunction. Design-Retrospective cohort study. Animals-27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0.26 ± 0.08 mg/kg [0.118 ± 0.036 mg/lb], PO, q 12 h).Procedures-Information on medical history, laboratory results, diagnostic imaging findings, treatments received, and survival time were obtained from medical records of cats that received pimobendan because of cardiac disease. When possible, additional follow-up information was obtained through telephone interviews with referring veterinarians and owners. Results-The mean ± SD age of all 27 cats was 8.9 ± 5.2 years. All cats had received several cardiac medications. Types of heart disease represented included unclassified cardio-myopathy (CM; n = 11 [41%]), dilated CM (8 [30%]), arrhythmogenic right ventricular CM (4 [15%]), congenital heart disease (3 [11%]), and hypertrophic CM with regional hypokinesis (1 [4%]). All cats had ventricular systolic dysfunction. One cat with systolic anterior motion of the mitral valve became severely hypotensive after initial administration of pimobendan and was excluded from the survival analysis. Median survival time was 167 days (95% confidence interval, 32 to 339 days).Conclusions and Clinical Relevance-Pimobendan appeared to be well tolerated in cats with heart failure characterized by ventricular systolic dysfunction of various etiologies. Cats with systolic anterior motion of the mitral valve may develop systemic hypotension when treated with pimobendan. Additional studies are needed to establish dosages for pimobendan and its effects before it can be recommended for treatment of cats with CHF.

UR - http://www.scopus.com/inward/record.url?scp=84863216470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863216470&partnerID=8YFLogxK

U2 - 10.2460/javma.241.1.89

DO - 10.2460/javma.241.1.89

M3 - Article

C2 - 22720992

AN - SCOPUS:84863216470

VL - 241

SP - 89

EP - 94

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 1

ER -